Brief: FDA Accepts Supplemental New Drug Application For Arcutis’ Zoryve® (Roflumilast) Cream 0.3% For The Treatment Of Plaque Psoriasis In Children Ages 2 To 5
17/11/2025 13:15
Arcutis Biotherapeutics Inc ARQT.O: FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS’ ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5 ARCUTIS BIOTHERAPEUTICS INC - FDA SETS PDUFA TARGET DATE FOR JUNE 29, 2026 Source text: ID:nGNX1F2Cl3 Further company coverage: ARQT.O
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf